Corvus Nicks up on Releasing Preclinical Trial Data
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares just cleared breakeven Wednesday. The South San Francisco-based company, a clinical-stage biopharmaceutical concern, today announced preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis will be presented today in a poster session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is taking place June 11-14 in Barcelona. The poster will be presented by Gonçalo Boleto, M.D., MSc, a rheumatologist at Centro Académico de Medicina de Lisboa, Portugal. It was selected as a top 10 abstract by the Emerging EULAR Network, a network of young rheumatologists and researchers in the field of rheumatology in Europe and beyond.“There continues to be strong interest in the potential of ITK inhibition to provide a new approach to treating a broad range of diseases, including immune mediated fibrotic diseases such as systemic sclerosis,” said CEO Richard A. Miller. “We look forward to presenting preclinical data to the audience at EULAR demonstrating that soquelitinib, our lead ITK inhibitor, may prevent lung damage, inflammation and pulmonary hypertension caused by systemic sclerosis. While our main focus is developing soquelitinib via our registration Phase 3 trial in peripheral T cell lymphoma and Phase 1 trial in atopic dermatitis, we may explore the potential of ITK in systemic sclerosis in future clinical trials or via partnerships.”CRVS shares forged ahead 9.5 cents, or 2.2%, to $4.34.
Recent Posts
Europe Faces Most Difficult Moment in Bid to Avoid Split With US
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Hastings Racecourse in Vancouver to shut down permanently, operator says
Russia’s Vital Oil Trade With India Is Down, But Not Out
Copper Quest Closes $1,927,000 Private Placement
This TSX stock was up 17% this week and it could gain another 36%, analysts say
AMC Entertainment Holdings, Inc. Transfers the Majority of its Equity Investment in Hycroft Mining Holding Corporation to Sprott Mining for a Net Consideration of $24.1 million
Guardian Capital Announces Estimated 2025 Annual Non-Cash Distributions for Guardian Capital ETFs
Emera Renews At-The-Market Equity Program
CRA warns of ‘aggressive tax schemes’ involving critical illness insurance
